Código QR (código de barras bidimensional)

Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain

Respiratory syncytial virus (RSV) is the main cause of low respiratory tract infections in infants under one year of age. In the 2023/2024 season, the monoclonal antibody nirsevimab was available to protect children from RSV, and Spain has become one of the first countries worldwide to implement thi...

ver descrição completa

Na minha lista:
Principais autores: Jaime Jesús Pérez Martín, Matilde Zornoza Moreno
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2024-12-01
coleção:Human Vaccines & Immunotherapeutics
Assuntos:
Respiratory syncytial virus
nirsevimab
passive immunization
monoclonal antibody
public health
Acesso em linha:https://www.tandfonline.com/doi/10.1080/21645515.2024.2365804
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados